Novo Nordisk bets on RNA in several business areas

It is not just vaccine companies that see potential in using RNA technologies – Novo Nordisk also has agreements in place for the therapies.

Photo: Novo Nordisk/ PR

When Novo Nordisk entered into an agreement with US company Dicerna two years ago, it had seen the potential in manipulating RNA, like many other players in the industry.

Danish financial daily Børsen reports that the deal concerns a specific form of RNA technology, called RNA interference, or RNAi, which aims to reduce the production of damaging proteins. Karin Conde-Knape, Senior Vice President of Global Drug Discovery at Novo Nordisk, calls the approach "clearly exciting".

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs